The next step in guiding medical therapy is considering whether the patient is symptomatic. Two therapies are approved to reduce symptoms of claudication in PAD: cilostazol and pentoxifylline. Cilostazol appears to be effective but pentoxifylline provides little to no benefit. Cilostazol should be offered to patients who have lifestyle-limiting symptoms. In general, it has a favorable safety profile; however, some patients have gastrointestinal side effects. In addition, due to risks observed with other agents in this class, it should not be given to patients with heart failure.
Promoting an increased awareness and standardized approaches in diagnosing and treating peripheral artery disease